{
  "name": "Are We Cured Yet? — Research news",
  "reviewed_at": "2026-10-28",
  "coverage": "Curated research and development updates. News does not contribute to either counter. Company-reported claims are attributed to the developer.",
  "articles": [
    {
      "id": "rentosertib-phase-iii-2026",
      "published_at": "2026-07-07",
      "reviewed_at": "2026-10-28",
      "category": "Clinical trials",
      "title": "Rentosertib moves into Phase III development",
      "summary": "Insilico reports AI involvement in both target discovery and molecule design, and announced Phase III development in 2026.",
      "context": "Rentosertib is investigational. This development update is not a marketing approval or evidence of a cure.",
      "sources": [
        {
          "label": "Development update: developer report",
          "kind": "developer",
          "url": "https://insilico.com/news/xmjsn4l091-insilico-initiates-phase-iii-clinical-tr"
        },
        {
          "label": "Trial registry",
          "kind": "registry",
          "url": "https://clinicaltrials.gov/study/NCT07687459"
        }
      ]
    }
  ]
}